Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

NCT04060394 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: Phase I and Phase II: LAE001/prednisone + afuresertib

Sponsor

Laekna Limited